A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, NSCLC With Brain Metastases
Clinical trial NCT04460729 · WITHDRAWN
Trial details
- NCT number
- NCT04460729
- Sponsor
- Novartis Pharmaceuticals
- Status
- WITHDRAWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-11-11
- Primary completion
- 2023-11-17
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.